8-K: Atossa Therapeutics Prioritizes Metastatic Breast Cancer Indication for (Z)-Endoxifen, Continues FDA Engagement

Atossa Therapeutics shifts focus to metastatic breast cancer for (Z)-endoxifen, aiming for faster regulatory approval while pursuing additional indications with the FDA.

Summary

• Atossa Therapeutics is prioritizing the development of (Z)-endoxifen for metastatic breast cancer.
• The company believes this strategy offers a more efficient regulatory path to deliver the drug to patients with urgent needs.
• Atossa plans to continue working with the FDA to advance (Z)-endoxifen for other indications, including breast cancer prevention and neoadjuvant therapy.
• Early-stage clinical trials have shown promising results, including improved progression-free survival and a favorable safety profile.
• The company is actively engaging with the FDA to define a regulatory path forward for additional indications based on compelling data released at the end of 2024.
• Atossa remains committed to demonstrating the broad clinical utility of (Z)-endoxifen across the breast cancer treatment paradigm.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Atossa Therapeutics, highlighting promising clinical data and a strategic shift to a more efficient regulatory pathway. The management's comments are optimistic, and the focus on addressing an unmet medical need is likely to be well-received by investors.

Positives

• (Z)-endoxifen has shown encouraging results in early-stage trials, including improved progression-free survival.
• The drug has demonstrated a favorable safety profile, comparable to tamoxifen.
• Pursuing a metastatic indication may offer a more efficient regulatory pathway.
• Atossa is actively engaging with the FDA to expand (Z)-endoxifen's use to other indications.
• Data suggests (Z)-endoxifen can significantly reduce breast tissue density and estrogen receptor activity, key risk factors for developing breast cancer.
• Data from early-stage patients indicate that the 4-week Ki-67 10% response rate remained consistently above 85 percent across all dose levels, regardless of the presence of ovarian function.

Risks

• The forward-looking statements in the press release are subject to risks and uncertainties that may cause actual results to differ materially from those projected or anticipated.
• These risks include the ability to obtain patent coverage, macroeconomic conditions, actions by the FDA, and the ability to successfully develop and commercialize new therapeutics.

Future Outlook

Atossa Therapeutics plans to provide future updates as they execute their plan to advance (Z)-endoxifen into a metastatic breast cancer indication and expand its role across the full spectrum of breast cancer prevention and treatment.

Management Comments

• Dr. Steven Quay, Chairman and Chief Executive Officer of Atossa Therapeutics, stated: 'Our decision to advance (Z)-endoxifen into a metastatic breast cancer indication underscores our unwavering commitment to developing a best-in-class therapy for women facing this devastating disease.'
• Dr. Steven Quay stated: 'The encouraging clinical data that has been generated to date supports the potential of (Z)-endoxifen to provide a meaningful benefit to patients who have exhausted other treatment options.'
• Dr. Steven Quay stated: 'By pursuing this strategy, we believe we are not only addressing an urgent medical need but also fortifying the path forward for expanding (Z)-endoxifens role across the full spectrum of breast cancer prevention and treatment.'

Industry Context

This announcement reflects a growing trend in the biopharmaceutical industry to focus on areas of high unmet medical need, such as metastatic breast cancer, and to seek more efficient regulatory pathways for drug approval. Companies like Puma Biotechnology, with Nerlynx, have also targeted specific breast cancer subtypes. Atossa's approach aligns with this trend by prioritizing a metastatic indication to potentially accelerate the availability of (Z)-endoxifen to patients.

Comparison to Industry Standards

• The reported PFS of 7.2 months with (Z)-endoxifen in CDK4/6i-naive patients compares favorably to the PFS observed with tamoxifen (2.4 months) and suggests a potential advantage in this patient population.
• Other SERMs, such as tamoxifen and raloxifene, are established treatments for breast cancer, but (Z)-endoxifen's higher potency may offer improved efficacy.
• The Ki-67 response rate of over 85% in early-stage patients is a positive indicator of (Z)-endoxifen's ability to reduce tumor proliferation, which is comparable to results seen with other neoadjuvant therapies.

Stakeholder Impact

• Shareholders may benefit from the potential for faster regulatory approval and commercialization of (Z)-endoxifen.
• Patients with metastatic breast cancer may have access to a new treatment option with improved efficacy and a favorable safety profile.
• The company's employees may be impacted by the strategic shift and the focus on metastatic breast cancer.

Next Steps

• Atossa Therapeutics plans to continue engaging with the FDA to further define a regulatory path forward for additional indications.
• The company will provide future updates as they execute their plan to advance (Z)-endoxifen into a metastatic breast cancer indication.

Key Dates